Insider Trading Activity For Endonovo Therapeutics Inc (NASDAQ:ENDV)
Michael Scott Mann , Insider of Endonovo Therapeutics Inc (NASDAQ:ENDV) reportedly Bought 18,000 shares of the company’s stock at an average price of 0.06 for a total transaction amount of $1,080.00 SEC Form
Analyst Ratings For Endonovo Therapeutics Inc (NASDAQ:ENDV)
These are No ratings tracked in the last 12 months. .
The current consensus rating for Endonovo Therapeutics Inc (NASDAQ:ENDV) is N/A (Score: NaN) with a consensus target price of N/A
About Endonovo Therapeutics Inc (NASDAQ:ENDV)
Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology company developing a bioelectronic approach to regenerative medicine. The Company operates through two segments: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. Its Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Its Cytotronics platform is being developed to create biologically potent cell therapies. It is using this technology to create a therapy for the treatment of Graft-Versus-Host Disease (GvHD), a rare complication following allogeneic tissue transplants. Its Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.
Recent Trading Activity for Endonovo Therapeutics Inc (NASDAQ:ENDV)
Shares of Endonovo Therapeutics Inc closed the previous trading session at 0.0529 up +0.0004 0.80% with 1,575,201 shares trading hands.